Eli Lilly stock soars to record high on obesity drug portfolio

Name: Eli Lilly stock soars to record high on obesity drug portfolio
Uploaded: 2025-11-19T16:53:06Z
Duration: 27 s
Description: Lauren Simonetti reports on Eli Lilly's stock reaching a new record high, surpassing $1,000 per share. This surge is attributed to the success of its obesity drug portfolio, including Mounjaro and Zepbound, with analysts predicting a further increase to $1,182 as the company is expected to reach 18 million people and generate $101 billion in peak revenue.

Varney & Company · FBN · Nov 19, 2025 · 27sSign Up Now

Already a subscriber?

Lauren Simonetti reports on Eli Lilly's stock reaching a new record high, surpassing $1,000 per share. This surge is attributed to the success of its obesity drug portfolio, including Mounjaro and Zepbound, with analysts predicting a further increase to $1,182 as the company is expected to reach 18 million people and generate $101 billion in peak revenue.